ArticleEuropean heart journal. Digital health2022
Daily ambulatory remote monitoring system for drug escalation in chronic heart failure with reduced ejection fraction: pilot phase of DAVID-HF study.
Article in European heart journal. Digital health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial
Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Wearable Devices for Remote Monitoring of Chronic Diseases: Systematic Review.JMIR mHealth and uHealth · 2026Pooled it
- Cardiac Resynchronization as an Enabler of ARNI Efficacy: Insights From a Real-World Cohort.Journal of arrhythmia · 2026Article
- Challenges and potential of using digital biomarkers in healthcare and clinical trials.Communications medicine · 2026Review
- Noninvasive biometric monitoring technologies for patients with heart failure.Heart failure reviews · 2025Review
- Review
- A scoping review on advancements in noninvasive wearable technology for heart failure management.NPJ digital medicine · 2024Article
- Recent Advances in the Wearable Devices for Monitoring and Management of Heart Failure.Reviews in cardiovascular medicine · 2024Review
- Digital Solutions to Optimize Guideline-Directed Medical Therapy Prescriptions in Heart Failure Patients: Current Applications and Future Directions.Current heart failure reports · 2024Review
- Challenge of Optimizing Medical Therapy in Heart Failure: Unlocking the Potential of Digital Health and Patient Engagement.Journal of the American Heart Association · 2024Article
- A Heart Failure Smartphone Application That Nudges Patients/Physicians Toward Optimal Medical Therapy - Development and Usability Study.Circulation reports · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Underutilization of guideline-directed heart failure with reduced ejection fraction (HFrEF) medications contributes to poor outcomes. Methods and results: A pilot study to evaluate the safety and efficacy of a home-based remote monitoring system for HFrEF management was performed. The system included wearable armband monitors paired with the smartphone application. An HFrEF medication titration algorithm was used to adjust medication daily. The primary endpoint was HFrEF medication utilization at 120 days. Twenty patients (60.5 ± 8.2 years, men: 85%) with HFrEF were recruited. All received angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI) at recruitment; 45% received ≥50% maximal targeted dose (MTD) with % MTD of 44.4 ± 31.7%. At baseline, 90 and 70% received beta-adrenergic blocker and mineralocorticoid receptor antagonist (MRA), 35% received ≥50% MTD beta-adrenergic blocker with % MTD of 34.1 ± 29.6%, and 25% received ≥50% MTD MRA with % MTD of 25.0 ± 19.9%. At 120 days, 70% received ≥50% MTD ACEI/ARB/ARNI ( Conclusion: Heart failure with reduced ejection fraction medication escalation with remote monitoring appeared feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.